Royalty Pharma plc Class A (RPRX)
NASDAQ · Manufacturing · Pharmaceutical preparations
RPRX price, last 12 months
Key stats
- Previous close
- $68.67
- Open
- $68.42
- Day range
- $67.57 – $68.98
- 52-week range
- $37.31 – $70.37
- Volume
- 3.3M
- Avg volume (20 days)
- 3.5M
- Market cap
- $30.9B
Performance
Technicals and fundamentals
About Royalty Pharma plc Class A
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $30.9B